Elanco Animal Health (NYSE:ELAN – Get Free Report) had its price target decreased by investment analysts at Piper Sandler from $19.00 to $16.00 in a research note issued on Monday, Benzinga reports. The firm presently has a “neutral” rating on the stock. Piper Sandler’s price objective points to a potential upside of 10.88% from the stock’s previous close.
Separately, Barclays dropped their price objective on Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating on the stock in a research note on Friday. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.57.
Read Our Latest Stock Analysis on ELAN
Elanco Animal Health Stock Performance
ELAN opened at $14.43 on Monday. Elanco Animal Health has a twelve month low of $8.52 and a twelve month high of $18.80. The stock has a market cap of $7.13 billion, a PE ratio of -5.45, a price-to-earnings-growth ratio of 1.40 and a beta of 1.42. The business’s 50 day moving average is $16.43 and its 200-day moving average is $15.71. The company has a current ratio of 3.29, a quick ratio of 1.96 and a debt-to-equity ratio of 0.95.
Elanco Animal Health (NYSE:ELAN – Get Free Report) last announced its earnings results on Wednesday, May 8th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.26 by $0.08. The firm had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.18 billion. Elanco Animal Health had a negative net margin of 29.83% and a positive return on equity of 5.98%. Elanco Animal Health’s revenue was down 4.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.45 EPS. On average, analysts predict that Elanco Animal Health will post 0.93 earnings per share for the current year.
Insiders Place Their Bets
In other news, Director William F. Doyle purchased 15,000 shares of the business’s stock in a transaction dated Tuesday, May 21st. The stock was bought at an average cost of $16.98 per share, with a total value of $254,700.00. Following the purchase, the director now directly owns 76,330 shares of the company’s stock, valued at $1,296,083.40. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.57% of the company’s stock.
Hedge Funds Weigh In On Elanco Animal Health
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Hunter Associates Investment Management LLC increased its holdings in shares of Elanco Animal Health by 5.1% during the 1st quarter. Hunter Associates Investment Management LLC now owns 16,600 shares of the company’s stock worth $269,000 after purchasing an additional 800 shares during the period. Treasurer of the State of North Carolina boosted its position in shares of Elanco Animal Health by 0.5% during the 3rd quarter. Treasurer of the State of North Carolina now owns 221,460 shares of the company’s stock valued at $2,489,000 after acquiring an additional 1,107 shares in the last quarter. Bfsg LLC boosted its holdings in Elanco Animal Health by 8.2% during the first quarter. Bfsg LLC now owns 14,885 shares of the company’s stock valued at $242,000 after purchasing an additional 1,125 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Elanco Animal Health by 10.2% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 12,123 shares of the company’s stock worth $181,000 after buying an additional 1,127 shares in the last quarter. Finally, Commerce Bank grew its position in Elanco Animal Health by 3.8% in the fourth quarter. Commerce Bank now owns 33,665 shares of the company’s stock valued at $502,000 after acquiring an additional 1,223 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.
Elanco Animal Health Company Profile
(Get Free Report)
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.
Read More
Receive News & Ratings for Elanco Animal Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Elanco Animal Health and related companies with MarketBeat.com’s FREE daily email newsletter.